Protease For the Beginners
•
0 likes•122 views
This document discusses treatments for castration-resistant prostate cancer (CRPC). It notes that while many patients initially respond to androgen deprivation therapy for metastatic prostate cancer, nearly all will eventually become resistant. The document reviews several agents that have been approved to treat metastatic CRPC based on clinical trials, including mitoxantrone, docetaxel, cabazitaxel, and sipuleucel-T. It provides context on the historical lack of effective chemotherapy for prostate cancer and improved survival benefits shown for newer agents. The overview aims to summarize key clinical trials of current and investigational therapies for CRPC.
Report
Share
Report
Share
Download to read offline
![Protease For the Beginners
Se Joong Kim, Sunshine Il Kim
Division of Urology, Ajou University School of Drugs, Suwon, Korea
Prostate most cancers is the most typical cancer in males in United States and the fifth most
frequent cancer in men in Korea. Even though the greater part of individuals with metastatic
prostate cancer at first react to androgen deprivation remedy, nearly all clients will ultimately
progress to produce castration-resistant prostate most cancers (CRPC). Remedy choices for
CRPC continue being minimal. Prostate cancer was deemed unresponsive to chemotherapy
right up until the mid-nineties, when mitoxantrone merged with prednisone was proven to
play a part in the palliative treatment method of patients with CRPC. In 2004, two huge
randomized clinical trials demonstrated for the first time a little but important survival gain of
docetaxel-based mostly chemotherapy in contrast with mitoxantrone in sufferers with
metastatic CRPC. Not too long ago, cabazitaxel was shown to increase survival in patients
with metastatic CRPC who progressed after docetaxel-based chemotherapy. Sipuleucel-T
was also demonstrated to enhance all round survival in patients with asymptomatic or
minimally symptomatic metastatic CRPC. Along with mitoxantrone and docetaxel,
cabazitaxel and sipuleucel-T are now approved for use in metastatic CRPC by the US Meals
and Drug Administration. There have been numerous earlier-phase medical trials of several
agents for the treatment of CRPC, and some are in phase III advancement. This overview
centers on the essential scientific trials of different therapy alternatives of CRPC currently in
use and below investigation. Important Terms: Drug treatment method Immunotherapy
Molecular specific remedy Prostatic neoplasms Survival
This is an Open Entry post dispersed beneath the conditions of the Creative Commons
Attribution Non-Industrial License (http://creativecommons.org/licenses/by-nc/three.) which
permits unrestricted non-business use, distribution, and reproduction in any medium,
provided the unique operate is effectively cited.
Post Record: obtained 9 February, 2011 recognised 21 February, 2011
Corresponding Writer: Se Joong Kim Section of Urology, Ajou College University of
Medicine, San five, Wonchon-dong, Yeongtong-gu, Suwon 443-721, Korea TEL: +eighty two-
31-219-5272 FAX: +eighty two-31-219-5276 E-mail: sejoong@ajou.ac.kr
INTRODUCTION
Prostate cancer is the most typical most cancers and the second most common cause of
cancer-connected dying in males in United States [1]. Prostate most cancers is now the fifth
most common cancer in men in Korea [4]. Given that the landmark reports of Huggins and
Hodges shown the advantageous outcomes of surgical castration and estrogen
administration in sufferers with metastatic prostate cancer in 1941 [5], androgen deprivation
therapy (ADT) has been the mainstay of treatment method for metastatic prostate cancer
[six-eight]. Even though the greater part of patients](https://image.slidesharecdn.com/proteaseavailableforbeginners-20121129-135627-121128235639-phpapp02/85/Protease-For-the-Beginners-1-320.jpg)
![with metastatic illness originally respond to ADT, nearly all patients will sooner or later
progress after an common of eighteen to 24 months, despite upkeep of castrate serum
testosterone amounts [9]. This medical condition has been explained as androgen-unbiased
or hormone-refractory prostate cancer (HRPC). Even so, these previously used phrases
have largely been replaced with castration-resistant prostate cancer (CRPC), with the
attention of the persistent androgen receptor signaling exercise regardless of castrate serum
testosterone amounts [six,8,10-13]. Remedy options for CRPC continue being minimal, and
the prognosis of sufferers with CRPC is dismal, with a median survival of 12 to 18 months
[nine,ten]. CCR5selleck chemicals|learn, Capecitabine solubility, Proteasefind out the facts](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Protease Suitable for Beginners
1) Prostate cancer is the most common cancer in men in the United States and the fifth most common in Korea. While most patients initially respond well to androgen deprivation therapy for metastatic prostate cancer, nearly all will eventually develop castration-resistant prostate cancer (CRPC).
2) For many years, treatment options for CRPC were limited to mitoxantrone and prednisone. However, in 2004 clinical trials showed docetaxel chemotherapy provided a small survival advantage over mitoxantrone. More recently, cabazitaxel and sipuleucel-T were also approved for metastatic CRPC based on clinical trial results showing they improved survival.
3) The review discusses past and current treatment
Local Therapies for Uveal Melanoma Liver Metastases
Darren Kies, MD, interventional radiologist at Winship Cancer Institute of Emory University presents Local Therapies for Uveal Melanoma Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Application of immunotherapy therapeutics in prostate adenocarcinoma slides
This document provides a literature review on the application of antigen-specific immunotherapy therapeutics in prostate adenocarcinoma. It first discusses prostate cancer as a worldwide health problem and how it is diagnosed using digital rectal exams, PSA tests, and biopsies. It then explains how prostate cancer is driven by androgen receptor signaling and describes current treatment options and their limitations. Finally, it introduces antigen-specific immunotherapy as a potential solution, describing the ProstVac VF vaccine clinical trials which demonstrated improved overall survival rates for metastatic castration-resistant prostate cancer patients.
Bibliography: Cancer Ver 1.2
This document provides a bibliography of research papers related to cancer organized by topic. It includes 3-7 references for each of 17 cancer-related topics, such as 3D tumor imaging, angiogenesis, bladder cancer, breast cancer, contrast imaging, and others. The references provided for each topic are journal articles published between 2005-2010 that describe research on imaging, molecular markers, treatment responses, and other aspects of various cancers.
VAR
The document analyzes Varian Medical Systems, a manufacturer of cancer treatment devices. It recommends exiting the position due to several factors, including domestic headwinds in the hospital industry, the re-emergence of an excise tax that will reduce cash flow, and emerging competitors in proton therapy eroding Varian's market share as costs are reduced. It also notes Varian has failed to deliver on past thesis points and upside catalysts.
Cardio tox
This systematic review and meta-analysis examined the risk of early and late cardiotoxicity from anthracycline agents used to treat cancers like breast cancer and lymphoma. The analysis included 55 randomized controlled trials. It found that anthracycline regimens carried a significantly higher risk of clinical cardiotoxicity compared to non-anthracycline regimens or mitoxantrone. Risk was lower for epirubicin vs doxorubicin, liposomal doxorubicin vs non-liposomal doxorubicin, and when cardioprotective agents were used. A similar pattern was seen for subclinical cardiotoxicity. However, evidence was not deemed sufficiently robust to support clear recommendations or routine use of protective measures due
breast and prostate cancer.
This document provides information about breast cancer and prostate cancer. It discusses the types, stages, risk factors, symptoms, diagnosis, and treatment of breast cancer. It also discusses statistics on breast cancer worldwide and in Guyana. For breast cancer in men, it covers what it is, signs and symptoms, and how it is diagnosed and treated. Prostate cancer is also briefly introduced.
Primary Prevention: A National Call to Action - Dr. Jeff Gershenwald
Dr. Jeff Gershenwald presents a recap of the Surgeon General's Call to Action at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Recommended
Protease Suitable for Beginners
1) Prostate cancer is the most common cancer in men in the United States and the fifth most common in Korea. While most patients initially respond well to androgen deprivation therapy for metastatic prostate cancer, nearly all will eventually develop castration-resistant prostate cancer (CRPC).
2) For many years, treatment options for CRPC were limited to mitoxantrone and prednisone. However, in 2004 clinical trials showed docetaxel chemotherapy provided a small survival advantage over mitoxantrone. More recently, cabazitaxel and sipuleucel-T were also approved for metastatic CRPC based on clinical trial results showing they improved survival.
3) The review discusses past and current treatment
Local Therapies for Uveal Melanoma Liver Metastases
Darren Kies, MD, interventional radiologist at Winship Cancer Institute of Emory University presents Local Therapies for Uveal Melanoma Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Application of immunotherapy therapeutics in prostate adenocarcinoma slides
This document provides a literature review on the application of antigen-specific immunotherapy therapeutics in prostate adenocarcinoma. It first discusses prostate cancer as a worldwide health problem and how it is diagnosed using digital rectal exams, PSA tests, and biopsies. It then explains how prostate cancer is driven by androgen receptor signaling and describes current treatment options and their limitations. Finally, it introduces antigen-specific immunotherapy as a potential solution, describing the ProstVac VF vaccine clinical trials which demonstrated improved overall survival rates for metastatic castration-resistant prostate cancer patients.
Bibliography: Cancer Ver 1.2
This document provides a bibliography of research papers related to cancer organized by topic. It includes 3-7 references for each of 17 cancer-related topics, such as 3D tumor imaging, angiogenesis, bladder cancer, breast cancer, contrast imaging, and others. The references provided for each topic are journal articles published between 2005-2010 that describe research on imaging, molecular markers, treatment responses, and other aspects of various cancers.
VAR
The document analyzes Varian Medical Systems, a manufacturer of cancer treatment devices. It recommends exiting the position due to several factors, including domestic headwinds in the hospital industry, the re-emergence of an excise tax that will reduce cash flow, and emerging competitors in proton therapy eroding Varian's market share as costs are reduced. It also notes Varian has failed to deliver on past thesis points and upside catalysts.
Cardio tox
This systematic review and meta-analysis examined the risk of early and late cardiotoxicity from anthracycline agents used to treat cancers like breast cancer and lymphoma. The analysis included 55 randomized controlled trials. It found that anthracycline regimens carried a significantly higher risk of clinical cardiotoxicity compared to non-anthracycline regimens or mitoxantrone. Risk was lower for epirubicin vs doxorubicin, liposomal doxorubicin vs non-liposomal doxorubicin, and when cardioprotective agents were used. A similar pattern was seen for subclinical cardiotoxicity. However, evidence was not deemed sufficiently robust to support clear recommendations or routine use of protective measures due
breast and prostate cancer.
This document provides information about breast cancer and prostate cancer. It discusses the types, stages, risk factors, symptoms, diagnosis, and treatment of breast cancer. It also discusses statistics on breast cancer worldwide and in Guyana. For breast cancer in men, it covers what it is, signs and symptoms, and how it is diagnosed and treated. Prostate cancer is also briefly introduced.
Primary Prevention: A National Call to Action - Dr. Jeff Gershenwald
Dr. Jeff Gershenwald presents a recap of the Surgeon General's Call to Action at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Prostate Cancer Resources
September is National Prostate Cancer Awareness Month. Here are some helpful resources in honor of Prostate Cancer Awareness Month.
Adjuvant therapy - Dr. Roda Amaria
Dr. Roda Amaria presents the latest on adjuvant therapy for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Prostate MDT workshop 16 nov 17 queries
1) The document discusses challenges with multi-disciplinary team meetings for prostate cancer including not having enough time to discuss each patient and missing key information.
2) It provides examples of cases to illustrate how MRI and targeted biopsies can provide more accurate risk stratification compared to standard biopsies alone. This includes finding higher grade cancers.
3) Treatment options for prostate cancer are varied and patient preferences should help guide decision making, as the long term outcomes of different approaches are unclear. Biomarkers may also provide additional information beyond pathology results.
Prostate Cancer Treatment Options
This document discusses treatment options for prostate cancer. It provides an overview of prostate cancer statistics and factors considered for treatment selection such as cancer stage and Gleason score. Main treatment options described include watchful waiting, surgery to remove the prostate, external beam radiation therapy, brachytherapy which implants radioactive seeds in the prostate, proton therapy which uses particle acceleration, and stereotactic body radiation therapy. Each treatment option outlines procedures, recovery times, and potential side effects.
Stereotactic Radiotherapy of Recurrent Malignant Gliomas Clinical White Paper
Learn more: https://www.brainlab.com/intraoperative-mri
Tumors of the central nervous system (CNS) represent approximately 176,000 newly diagnosed cases worldwide per year, with an estimated annual mortality of 128,000. Malignant gliomas comprise 30% of all primary CNS tumors and remain one of the greatest challenges in oncology today, despite access to state-of-the-art surgery, imaging, radiotherapy and chemotherapy.
Lung cancer
Lung cancer was rare prior to 1900 but became a leading cause of cancer death in the mid-20th century due to tobacco consumption. Tobacco smoking remains the primary cause of lung cancer worldwide, though 60% of new lung cancers in the US occur in former or never smokers. There are two main types of lung cancer - non-small cell lung cancer (NSCLC) which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and small cell lung cancer. Molecular profiling of mutations has identified subsets of NSCLC and helped develop targeted therapies, though transformation between cancer types can occur. Aberrant miRNA and methylation expression are also involved in lung cancer pathogenesis and have potential as biomarkers.
What Is Cancer
Cancer is caused by abnormal cell growth that spreads uncontrollably. It develops through a complex interaction between genes, environment, and chance. Cancer cells do not die like normal cells and continue growing and dividing in a disorderly fashion. The media needs to accurately report on cancer research studies and not oversimplify results or mislead the public. The UK has higher cancer death rates than some other countries, which may be partly due to lower spending on cancer medications.
Measuring patient experience
How well does the UK diagnose and treat cancer – and is there a postcode lottery with regional variations in the quality of care?
POSTER Group18 Predicting pancreatic cancer_finalversion
This document describes a study that used supervised topic modeling to predict pancreatic cancer from electronic medical record data. The study analyzed diagnosis codes from 189 pancreatic cancer patients and 1,000 control patients. A supervised topic model identified latent patterns in the data related to pancreatic cancer with good predictive performance and interpretability. Essential hypertension was identified as a risk factor. The model could help identify pancreatic cancer in earlier treatable stages.
Update in oncology
This document provides an overview of cancer including its causes, diagnosis, treatment and prevention. It discusses that cancer is caused by genetic mutations that disrupt normal cell growth and can be due to factors such as viruses, radiation, chemicals and heredity. The diagnosis of cancer involves tissue biopsies, imaging tests and tumor marker tests to determine the cancer type and stage. Treatment may include surgery, radiation therapy, chemotherapy and targeted therapies to cure early stage cancer or control later stage cancer. Screening tests can help detect some cancer types early when they are more likely to be cured. Prevention strategies include avoiding risk factors, vaccinations, chemoprevention and healthy behaviors.
Foley 2011 Cochrane protocol
This protocol summarizes a planned systematic review that will evaluate the effectiveness and safety of endothelin inhibitors for treating advanced prostate cancer. The review aims to assess how endothelin inhibitors impact overall survival, prostate cancer-specific survival, progression-free survival, adverse events, target lesions identified on imaging, molecular biomarkers like PSA and bone alkaline phosphatase levels, and quality of life. The review will focus on advanced prostate cancer that has become metastatic or castration-resistant.
Rectal cancer 2
The document discusses a case of rectal cancer and provides information on imaging and treatment options for rectal cancer. It summarizes various studies on imaging modalities for staging rectal cancer such as ERUS, CT, and MRI. It also reviews studies on the role of adjuvant chemotherapy and chemoradiation therapy after surgery for rectal cancer. Alternative non-operative approaches for locally advanced rectal cancer are presented.
Chemotherapy of Head and neck cancers seminar
This document discusses chemotherapy for cancer treatment. It begins by defining chemotherapy and its origins. It then covers the cell cycle and tumor cell kinetics, different classes of chemotherapeutic agents (such as alkylating agents, antimetabolites, antitumor antibiotics), common agents used to treat head and neck cancers, and how patients receiving chemotherapy are managed orally. The document provides details on specific chemotherapy drugs, their mechanisms of action, dosages, and toxicities.
Ozioma Njoku
The document discusses adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC). It summarizes that the recognition of adjuvant chemotherapy improving survival after surgery for NSCLC was a major advancement. Specifically, administration of cisplatin-based doublet chemotherapy after complete resection of NSCLC stages I-IIIA has been associated with a 5-year survival increase. The most important meta-analysis, the LACE analysis, found that cisplatin-based doublet chemotherapy increased 5-year survival rates from 64%-67% for stage IB NSCLC, from 39%-49% for stage II, and from 26%-39% for stage III.
Survivorship Issues Genetics 2016
This document discusses genetics implications for survivorship programs. It highlights identifying patients who were previously missed for genetic testing and may benefit from re-testing given advances in panel testing. It also reviews managing hereditary cancer risks and addressing the psychosocial issues patients face, such as making difficult medical decisions, informing relatives, and dealing with feelings of guilt. Survivorship programs can help such patients navigate these medical and familial implications.
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...European School of Oncology
This document discusses the long term effects of androgen deprivation therapy (ADT) used to treat prostate cancer. It notes that ADT can result in increased bone loss and fractures in 12.6-19.4% of men within 5 years. ADT also increases the risks of metabolic syndrome, cardiovascular toxicity in 30% of men, increased risk of diabetes, reduced lean body mass, and central adiposity. The document recommends lifestyle interventions like exercise and nutrition advice to help prevent and manage these long term effects of ADT. It also advocates for a multidisciplinary approach including nursing assessment, data collection, and collaboration between primary care and other healthcare providers.Cancer
Cancer is characterized by uncontrolled growth and spread of abnormal cells. If left untreated, cancer can result in death. The document discusses several types of cancer including lung cancer, the leading cause of cancer death, and colon cancer, the second most common cancer. It also covers cancer statistics, risk factors, screening, treatment milestones, and specific cancers like lung and colon cancer. Preventable lifestyle factors contribute to nearly 1/3 of cancer deaths in the US. Early detection through screening improves diagnosis and survival rates.
Curriculum Vitae of Meng MB - 副本
This document is a curriculum vitae for Dr. Mao-Bin Meng. It lists his educational background, including medical degrees from Sichuan University and a Ph.D. in Radiation Biology. It details his professional experience, including current appointments as an Associate Professor at Tianjin Medical University Cancer Institute and previous roles. It also lists research funding he has received and publications, including papers in peer-reviewed journals.
Oncology Big Data: A Mirage or Oasis of Clinical Value?
The title of the presentation, Oncology Big Data: A Mirage or Oasis of Clinical Value, reflects what I believe the field of Oncology is challenged with on a growing basis, from a clinical and business side perspective.
cancer & chronic myeloed leukemia
Cancer is caused by rapid growth of abnormal cells that grow beyond their usual boundaries and can invade other parts of the body. Cancer is characterized by mutated genes called oncogenes that cause uncontrolled cell growth. Tumors can be benign if they remain confined or malignant if they invade other tissues and metastasize to spread to other organs through the bloodstream and lymph nodes. Cancer treatment may include surgery, radiation therapy to damage DNA, and chemotherapy to impair cell division using cytotoxic drugs. Pharmacogenomics aims to tailor treatments based on individual genetic profiles to increase drug effectiveness and reduce side effects.
Beer AACR article_May10_2011.full
This document summarizes the results of a randomized clinical trial investigating the autologous cellular immunotherapy sipuleucel-T in patients with androgen dependent prostate cancer. The trial did not meet its primary endpoint of showing a statistically significant difference in time to biochemical failure between the sipuleucel-T and control arms. However, patients receiving sipuleucel-T did experience a 48% increase in prostate specific antigen doubling time following testosterone recovery compared to the control arm. Treatment with sipuleucel-T was also associated with robust and sustained T cell immune responses against the immunizing antigen. The treatment was generally well tolerated with fatigue, chills, and pyrexia being the most common adverse events reported.
H0422050055
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay
More Related Content
What's hot
Prostate Cancer Resources
September is National Prostate Cancer Awareness Month. Here are some helpful resources in honor of Prostate Cancer Awareness Month.
Adjuvant therapy - Dr. Roda Amaria
Dr. Roda Amaria presents the latest on adjuvant therapy for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Prostate MDT workshop 16 nov 17 queries
1) The document discusses challenges with multi-disciplinary team meetings for prostate cancer including not having enough time to discuss each patient and missing key information.
2) It provides examples of cases to illustrate how MRI and targeted biopsies can provide more accurate risk stratification compared to standard biopsies alone. This includes finding higher grade cancers.
3) Treatment options for prostate cancer are varied and patient preferences should help guide decision making, as the long term outcomes of different approaches are unclear. Biomarkers may also provide additional information beyond pathology results.
Prostate Cancer Treatment Options
This document discusses treatment options for prostate cancer. It provides an overview of prostate cancer statistics and factors considered for treatment selection such as cancer stage and Gleason score. Main treatment options described include watchful waiting, surgery to remove the prostate, external beam radiation therapy, brachytherapy which implants radioactive seeds in the prostate, proton therapy which uses particle acceleration, and stereotactic body radiation therapy. Each treatment option outlines procedures, recovery times, and potential side effects.
Stereotactic Radiotherapy of Recurrent Malignant Gliomas Clinical White Paper
Learn more: https://www.brainlab.com/intraoperative-mri
Tumors of the central nervous system (CNS) represent approximately 176,000 newly diagnosed cases worldwide per year, with an estimated annual mortality of 128,000. Malignant gliomas comprise 30% of all primary CNS tumors and remain one of the greatest challenges in oncology today, despite access to state-of-the-art surgery, imaging, radiotherapy and chemotherapy.
Lung cancer
Lung cancer was rare prior to 1900 but became a leading cause of cancer death in the mid-20th century due to tobacco consumption. Tobacco smoking remains the primary cause of lung cancer worldwide, though 60% of new lung cancers in the US occur in former or never smokers. There are two main types of lung cancer - non-small cell lung cancer (NSCLC) which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and small cell lung cancer. Molecular profiling of mutations has identified subsets of NSCLC and helped develop targeted therapies, though transformation between cancer types can occur. Aberrant miRNA and methylation expression are also involved in lung cancer pathogenesis and have potential as biomarkers.
What Is Cancer
Cancer is caused by abnormal cell growth that spreads uncontrollably. It develops through a complex interaction between genes, environment, and chance. Cancer cells do not die like normal cells and continue growing and dividing in a disorderly fashion. The media needs to accurately report on cancer research studies and not oversimplify results or mislead the public. The UK has higher cancer death rates than some other countries, which may be partly due to lower spending on cancer medications.
Measuring patient experience
How well does the UK diagnose and treat cancer – and is there a postcode lottery with regional variations in the quality of care?
POSTER Group18 Predicting pancreatic cancer_finalversion
This document describes a study that used supervised topic modeling to predict pancreatic cancer from electronic medical record data. The study analyzed diagnosis codes from 189 pancreatic cancer patients and 1,000 control patients. A supervised topic model identified latent patterns in the data related to pancreatic cancer with good predictive performance and interpretability. Essential hypertension was identified as a risk factor. The model could help identify pancreatic cancer in earlier treatable stages.
Update in oncology
This document provides an overview of cancer including its causes, diagnosis, treatment and prevention. It discusses that cancer is caused by genetic mutations that disrupt normal cell growth and can be due to factors such as viruses, radiation, chemicals and heredity. The diagnosis of cancer involves tissue biopsies, imaging tests and tumor marker tests to determine the cancer type and stage. Treatment may include surgery, radiation therapy, chemotherapy and targeted therapies to cure early stage cancer or control later stage cancer. Screening tests can help detect some cancer types early when they are more likely to be cured. Prevention strategies include avoiding risk factors, vaccinations, chemoprevention and healthy behaviors.
Foley 2011 Cochrane protocol
This protocol summarizes a planned systematic review that will evaluate the effectiveness and safety of endothelin inhibitors for treating advanced prostate cancer. The review aims to assess how endothelin inhibitors impact overall survival, prostate cancer-specific survival, progression-free survival, adverse events, target lesions identified on imaging, molecular biomarkers like PSA and bone alkaline phosphatase levels, and quality of life. The review will focus on advanced prostate cancer that has become metastatic or castration-resistant.
Rectal cancer 2
The document discusses a case of rectal cancer and provides information on imaging and treatment options for rectal cancer. It summarizes various studies on imaging modalities for staging rectal cancer such as ERUS, CT, and MRI. It also reviews studies on the role of adjuvant chemotherapy and chemoradiation therapy after surgery for rectal cancer. Alternative non-operative approaches for locally advanced rectal cancer are presented.
Chemotherapy of Head and neck cancers seminar
This document discusses chemotherapy for cancer treatment. It begins by defining chemotherapy and its origins. It then covers the cell cycle and tumor cell kinetics, different classes of chemotherapeutic agents (such as alkylating agents, antimetabolites, antitumor antibiotics), common agents used to treat head and neck cancers, and how patients receiving chemotherapy are managed orally. The document provides details on specific chemotherapy drugs, their mechanisms of action, dosages, and toxicities.
Ozioma Njoku
The document discusses adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC). It summarizes that the recognition of adjuvant chemotherapy improving survival after surgery for NSCLC was a major advancement. Specifically, administration of cisplatin-based doublet chemotherapy after complete resection of NSCLC stages I-IIIA has been associated with a 5-year survival increase. The most important meta-analysis, the LACE analysis, found that cisplatin-based doublet chemotherapy increased 5-year survival rates from 64%-67% for stage IB NSCLC, from 39%-49% for stage II, and from 26%-39% for stage III.
Survivorship Issues Genetics 2016
This document discusses genetics implications for survivorship programs. It highlights identifying patients who were previously missed for genetic testing and may benefit from re-testing given advances in panel testing. It also reviews managing hereditary cancer risks and addressing the psychosocial issues patients face, such as making difficult medical decisions, informing relatives, and dealing with feelings of guilt. Survivorship programs can help such patients navigate these medical and familial implications.
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...European School of Oncology
This document discusses the long term effects of androgen deprivation therapy (ADT) used to treat prostate cancer. It notes that ADT can result in increased bone loss and fractures in 12.6-19.4% of men within 5 years. ADT also increases the risks of metabolic syndrome, cardiovascular toxicity in 30% of men, increased risk of diabetes, reduced lean body mass, and central adiposity. The document recommends lifestyle interventions like exercise and nutrition advice to help prevent and manage these long term effects of ADT. It also advocates for a multidisciplinary approach including nursing assessment, data collection, and collaboration between primary care and other healthcare providers.Cancer
Cancer is characterized by uncontrolled growth and spread of abnormal cells. If left untreated, cancer can result in death. The document discusses several types of cancer including lung cancer, the leading cause of cancer death, and colon cancer, the second most common cancer. It also covers cancer statistics, risk factors, screening, treatment milestones, and specific cancers like lung and colon cancer. Preventable lifestyle factors contribute to nearly 1/3 of cancer deaths in the US. Early detection through screening improves diagnosis and survival rates.
Curriculum Vitae of Meng MB - 副本
This document is a curriculum vitae for Dr. Mao-Bin Meng. It lists his educational background, including medical degrees from Sichuan University and a Ph.D. in Radiation Biology. It details his professional experience, including current appointments as an Associate Professor at Tianjin Medical University Cancer Institute and previous roles. It also lists research funding he has received and publications, including papers in peer-reviewed journals.
Oncology Big Data: A Mirage or Oasis of Clinical Value?
The title of the presentation, Oncology Big Data: A Mirage or Oasis of Clinical Value, reflects what I believe the field of Oncology is challenged with on a growing basis, from a clinical and business side perspective.
cancer & chronic myeloed leukemia
Cancer is caused by rapid growth of abnormal cells that grow beyond their usual boundaries and can invade other parts of the body. Cancer is characterized by mutated genes called oncogenes that cause uncontrolled cell growth. Tumors can be benign if they remain confined or malignant if they invade other tissues and metastasize to spread to other organs through the bloodstream and lymph nodes. Cancer treatment may include surgery, radiation therapy to damage DNA, and chemotherapy to impair cell division using cytotoxic drugs. Pharmacogenomics aims to tailor treatments based on individual genetic profiles to increase drug effectiveness and reduce side effects.
What's hot (20)
Stereotactic Radiotherapy of Recurrent Malignant Gliomas Clinical White Paper
Stereotactic Radiotherapy of Recurrent Malignant Gliomas Clinical White Paper
POSTER Group18 Predicting pancreatic cancer_finalversion
POSTER Group18 Predicting pancreatic cancer_finalversion
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...
MON 2011 - Slide 30 - S. Faithfull / D. Papageorgiou - Case presentations: Po...
Oncology Big Data: A Mirage or Oasis of Clinical Value?
Oncology Big Data: A Mirage or Oasis of Clinical Value?
Similar to Protease For the Beginners
Beer AACR article_May10_2011.full
This document summarizes the results of a randomized clinical trial investigating the autologous cellular immunotherapy sipuleucel-T in patients with androgen dependent prostate cancer. The trial did not meet its primary endpoint of showing a statistically significant difference in time to biochemical failure between the sipuleucel-T and control arms. However, patients receiving sipuleucel-T did experience a 48% increase in prostate specific antigen doubling time following testosterone recovery compared to the control arm. Treatment with sipuleucel-T was also associated with robust and sustained T cell immune responses against the immunizing antigen. The treatment was generally well tolerated with fatigue, chills, and pyrexia being the most common adverse events reported.
H0422050055
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay
Prostate cancer-double-vision-but-solitary-lesion
Abstract
A 53 year old man with a background of castrate-sensitive prostate cancer on intermittent androgen deprivation therapy (ADT) presented with right sixth nerve palsy secondary to a solitary right petroclival lesion involving adjacent dura and bone. The clinical and imaging characteristics of the lesion were consistent with a number of differential diagnoses (including metastatic prostate cancer, meningioma and chondrosarcoma). The patient initially declined biopsy and ADT was recommenced but the lesion continued to enlarge despite an excellent biochemical response. A subsequent biopsy of the petroclival mass demonstrated a WHO grade I meningioma and the patient proceeded to have definitive stereotactic radiotherapy. This case illustrates an unusual solitary skull base lesion in a man with prostate cancer. Whilst bony metastases, usually multiple, in the skeleton are common, solitary skull or brain lesions should be investigated as alternate diagnoses are likely in such circumstance.
How to have quality of life in Advanced ovarian malignancy
This document discusses advanced ovarian malignancy and improving quality of life. It notes that ovarian cancer is a leading cause of cancer death in women and is difficult to diagnose early. While most patients present with advanced disease, improvements in surgery and chemotherapy have increased survival rates to 45% at 5 years. Quality of life factors like physical, psychological, social and sexual issues are important to consider in treatment. Managing side effects, providing social support, and palliative care can help improve patient quality of life.
Establishment of a Rehabilitation Clinic for Colorectal Cancer. Will it End P...
Colorectal cancer (CRC) is the third most common diagnosis and the second most lethal malignancy in both men and women.
To establish a rehabilitation clinic in the oncology department in hospitals and address its positive effect on colorectal cancer patients’ need.
IJSR.pdf
This document reviews the evidence for managing locally advanced rectal cancers. It discusses how treatment has evolved from surgery alone to incorporating neoadjuvant radiation and chemotherapy. Neoadjuvant treatment has been shown to improve local control and survival compared to postoperative or adjuvant treatment. Achieving a pathological complete response after neoadjuvant therapy is associated with better long-term outcomes. Researchers have explored intensifying neoadjuvant treatment and increasing the interval before surgery to improve response rates. Accurately identifying patients who could avoid surgery through a "watch and wait" strategy depends on improved radiological assessment of tumor response.
Crimson Publishers-The Orthopedic Burden of U.S. Cancer Care
This document summarizes the orthopedic burden of cancer care in the United States. It notes that as cancer survivorship increases, orthopedists will increasingly treat long-term complications of cancer and its treatments. Many cancers commonly metastasize to bone, requiring orthopedic intervention. Chemotherapies can cause bone density loss, fractures, and other issues. The document outlines common primary bone cancers and soft tissue sarcomas, as well as electrolyte abnormalities, painful lesions, and spinal cord compression that orthopedists might encounter. It concludes by discussing long-term complications like bone density loss, degenerative joint disease, and increased injury risk that orthopedists must manage in cancer survivors.
Vital Signs Edition #2
The document discusses evidence that calls into question the theory that Avastin works as an anti-angiogenic drug by cutting off blood supply to tumors. Some studies show Avastin is more effective when added to weaker chemotherapy regimens, suggesting it may work by depleting the stromal layer surrounding tumors and allowing more chemotherapy to reach cancer cells. The debate over Avastin's mechanism of action will continue. The document also provides updates on clinical trials investigating drugs for lung cancer and pancreatic cancer that target the stromal tissue surrounding tumors.
Prostate Cancer - Current Approach and Future Perspective in Castration-Resis...
Prostate carcinoma is one of the most commonly diagnosed solid tumours in males worldwide. Selection of the treatment method is strictly dependent upon disease stage and the patient’s age. Availability of diagnostic tests is constantly increasing in clinical practice, allowing early diagnosis and better chances for complete and permanent recovery. In the case of locally advanced prostate carcinoma, radical surgery or radiotherapy is considered as the most effective therapeutic approach, whereas in metastatic prostate carcinoma, hormone therapy or androgen deprivation therapy (ADT) is the primary therapeutic option. Moreover, increased use of chemotherapy with docetaxel and cabazitaxel in clinical practice has resulted in better prognosis for patients in this advanced stage of the disease.
The biggest challenge for doctors and patients remains the treatment of hormone-resistant carcinoma (which very often is also metastatic). Concerns of today’s medicine regarding effective therapies for this type of disease have recently led to a significant increase in the number of papers/studies on new-generation biological treatments.
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Dr. Serge Jurasunas shares his Prostate Cancer Protocol in this paper, explaining the nature and treatment of Prostate Cancer from a Naturopathic Oncology Perspective. Professor Jurasunas is located in Lisbon Portugal and has lectured worldwide throughout his 50 years as a clinician.
He explains what can be done about the #1 cause of death in males even before lung cancer and what can be done, from the new perspective of Naturopathic Oncology.He offers an example, explains diagnostic procedures with Molecular markers and addresses detox, supplements and treatment.
Further information may be found in his new book, Health and Disease Begin in the Colon" and in his Blog: Naturopathiconcology.blogspot.com .
Digital version thesis Salvage for radiorecurrent prostate cancer, Max Peters
This document discusses salvage therapy for prostate cancer recurrences after primary radiotherapy. It notes that patients undergoing radiotherapy are at risk of recurrent disease, which is often confined to the prostate and eligible for salvage treatment. Traditionally, salvage modalities targeted the entire prostate due to difficulties assessing localized recurrences, but this resulted in significant toxicity rates. Recent advances in MRI and biopsy techniques allow for focal salvage treatments targeting only the recurrent tumor area, maintaining cancer control while decreasing toxicity. Focal salvage Iodine-125 brachytherapy appears able to provide durable disease control with minimized toxicity. However, dose constraints are needed for organs at risk to prevent complications, and constraints developed for primary radiotherapy may not apply
Carcinoma of Prostate
Carcinoma prostate is the most common cancer in men. Yet there are unresolved issues. It was thought that serum PSA levels would be diagnostic for this particular cancer. However, it has now been proven beyond doubt that it can be raised in many other conditions.
Protocol for the Treatment of Prostate Cancer
Professor of Naturopathic Oncology, Serge Jurasunas explains the nature of prostate cancer and outlines the unique protocols he utilizes at his Lisbon clinic. Additional information is available on his website: www.sergejurasunas.com
Cross trial
This document describes a study protocol for a randomized phase III clinical trial comparing neoadjuvant chemoradiation followed by surgery versus surgery alone in patients with adenocarcinoma or squamous cell carcinoma of the esophagus. The trial aims to enroll 350 patients total with 175 patients in each arm. The primary objective is to compare median survival rates and quality of life between the two treatment groups. Secondary objectives include comparing pathological responses, progression-free survival, number of complete resections, treatment toxicity, and costs. The chemoradiation regimen involves weekly paclitaxel and carboplatin chemotherapy with concurrent radiation over 5 weeks. Patients will then undergo surgery and be followed up for survival and quality of life outcomes
Prostatic cancer final presentation
This document discusses prostate cancer, including its causes, diagnosis, signs and symptoms, and treatment options. It begins with background information on the prostate gland and how cancer develops. Risk factors for prostate cancer are then outlined, such as age, race, and family history. Methods for diagnosis include digital rectal exam, PSA testing, and imaging. A case study is presented of a 66-year-old man whose tests revealed prostate cancer. The document concludes by emphasizing the importance of early detection and treatment to achieve the best outcomes.
Minimizing locoregional recurrences in colorectal cancer surgery
Colorectal cancer is a major cause of morbidity and mortality worldwide. The Indian scenario also shows a similar trend, and this has been attributed to the changing dietary patterns. Recurrence in colorectal cancer is associated with many factors, some related to the tumor itself and some to the surgical principles applied. Understanding these factors and application of sound surgical principles can go a long way in decreasing the incidence of colorectal cancer. Here, we highlight the main biological and technical factors implicated in the recurrence of colorectal cancer.
PIVOT
The document summarizes the key findings and implications of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). The trial found that for men with low-risk prostate cancer, radical prostatectomy did not provide a benefit over observation in reducing mortality rates. This suggests that observation may be a reasonable option for some low-risk prostate cancer patients over age 60. However, the trial also implied that radical prostatectomy may provide survival benefits for those with higher-risk disease. The document discusses several limitations of the PIVOT trial and ongoing debates around the management and treatment of localized prostate cancer.
Stroma Cells May Inhibit the Growth of Pancreatic Cancer Tumors
A study by Drs. Oberstein and Olive found that certain stromal cells in pancreatic tumors may inhibit, rather than support, cancer growth in the earlier stages of pancreatic ductal adenocarcinoma. When mice with pancreatic cancer and reduced stromal cells were treated with long-term chemotherapy, their survival decreased similar to results seen in human clinical trials. Further research indicates some stromal cell types can restrain pancreatic tumor development, disproving the common belief that stromal cells mainly promote cancer.
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Enrique Moreno Gonzalez
This document summarizes a prospective, randomized, phase II clinical trial that evaluated the efficacy and safety of neoadjuvant chemotherapy with or without rh-endostatin for breast cancer. 68 patients received either 3 cycles of docetaxel and epirubicin (DE) chemotherapy alone or DE chemotherapy combined with rh-endostatin. The combination therapy showed a higher objective response rate of 91% compared to 68% for chemotherapy alone, with more complete responses but no increase in adverse effects. The combination appeared to work better in premenopausal patients and those with better performance status.DrMyers PSA Relapse (Indigo)
Unfortunately, many patients develop an increasing PSA after surgery or radiation therapy. Because standard imaging techniques are so inadequate, it has been impossible to find the cancer until PSA levels exceed 20 ng/ml. In our talk, we will first review what are the current standard treatment options: prostate bed radiation therapy and hormonal therapy. We will then discuss new imaging techniques that have dramatically improved our ability to locate the cancer. These imaging techniques allow radiation to be highly focused on actual sites of disease and both increase cancer control and reduce side effects. Finally, we talk about approaches that can arrest the progression of the cancer and can thus avoid both radiation and hormonal therapy.
Similar to Protease For the Beginners (20)
How to have quality of life in Advanced ovarian malignancy
How to have quality of life in Advanced ovarian malignancy
Establishment of a Rehabilitation Clinic for Colorectal Cancer. Will it End P...
Establishment of a Rehabilitation Clinic for Colorectal Cancer. Will it End P...
Crimson Publishers-The Orthopedic Burden of U.S. Cancer Care
Crimson Publishers-The Orthopedic Burden of U.S. Cancer Care
Prostate Cancer - Current Approach and Future Perspective in Castration-Resis...
Prostate Cancer - Current Approach and Future Perspective in Castration-Resis...
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Digital version thesis Salvage for radiorecurrent prostate cancer, Max Peters
Digital version thesis Salvage for radiorecurrent prostate cancer, Max Peters
Minimizing locoregional recurrences in colorectal cancer surgery
Minimizing locoregional recurrences in colorectal cancer surgery
Stroma Cells May Inhibit the Growth of Pancreatic Cancer Tumors
Stroma Cells May Inhibit the Growth of Pancreatic Cancer Tumors
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Protease For the Beginners
- 1. Protease For the Beginners Se Joong Kim, Sunshine Il Kim Division of Urology, Ajou University School of Drugs, Suwon, Korea Prostate most cancers is the most typical cancer in males in United States and the fifth most frequent cancer in men in Korea. Even though the greater part of individuals with metastatic prostate cancer at first react to androgen deprivation remedy, nearly all clients will ultimately progress to produce castration-resistant prostate most cancers (CRPC). Remedy choices for CRPC continue being minimal. Prostate cancer was deemed unresponsive to chemotherapy right up until the mid-nineties, when mitoxantrone merged with prednisone was proven to play a part in the palliative treatment method of patients with CRPC. In 2004, two huge randomized clinical trials demonstrated for the first time a little but important survival gain of docetaxel-based mostly chemotherapy in contrast with mitoxantrone in sufferers with metastatic CRPC. Not too long ago, cabazitaxel was shown to increase survival in patients with metastatic CRPC who progressed after docetaxel-based chemotherapy. Sipuleucel-T was also demonstrated to enhance all round survival in patients with asymptomatic or minimally symptomatic metastatic CRPC. Along with mitoxantrone and docetaxel, cabazitaxel and sipuleucel-T are now approved for use in metastatic CRPC by the US Meals and Drug Administration. There have been numerous earlier-phase medical trials of several agents for the treatment of CRPC, and some are in phase III advancement. This overview centers on the essential scientific trials of different therapy alternatives of CRPC currently in use and below investigation. Important Terms: Drug treatment method Immunotherapy Molecular specific remedy Prostatic neoplasms Survival This is an Open Entry post dispersed beneath the conditions of the Creative Commons Attribution Non-Industrial License (http://creativecommons.org/licenses/by-nc/three.) which permits unrestricted non-business use, distribution, and reproduction in any medium, provided the unique operate is effectively cited. Post Record: obtained 9 February, 2011 recognised 21 February, 2011 Corresponding Writer: Se Joong Kim Section of Urology, Ajou College University of Medicine, San five, Wonchon-dong, Yeongtong-gu, Suwon 443-721, Korea TEL: +eighty two- 31-219-5272 FAX: +eighty two-31-219-5276 E-mail: sejoong@ajou.ac.kr INTRODUCTION Prostate cancer is the most typical most cancers and the second most common cause of cancer-connected dying in males in United States [1]. Prostate most cancers is now the fifth most common cancer in men in Korea [4]. Given that the landmark reports of Huggins and Hodges shown the advantageous outcomes of surgical castration and estrogen administration in sufferers with metastatic prostate cancer in 1941 [5], androgen deprivation therapy (ADT) has been the mainstay of treatment method for metastatic prostate cancer [six-eight]. Even though the greater part of patients
- 2. with metastatic illness originally respond to ADT, nearly all patients will sooner or later progress after an common of eighteen to 24 months, despite upkeep of castrate serum testosterone amounts [9]. This medical condition has been explained as androgen-unbiased or hormone-refractory prostate cancer (HRPC). Even so, these previously used phrases have largely been replaced with castration-resistant prostate cancer (CRPC), with the attention of the persistent androgen receptor signaling exercise regardless of castrate serum testosterone amounts [six,8,10-13]. Remedy options for CRPC continue being minimal, and the prognosis of sufferers with CRPC is dismal, with a median survival of 12 to 18 months [nine,ten]. CCR5selleck chemicals|learn, Capecitabine solubility, Proteasefind out the facts